Discovery of the First Potent and Selective Small Molecule Opioid Receptor-like (ORL1) Antagonist: 1-[(3R,4R)-1-Cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl- 1,3-dihydro-2H-benzimidazol-2-one (J-113397)

Citations Over TimeTop 10% of 1999 papers

Abstract

ADVERTISEMENT RETURN TO ISSUELetterNEXTDiscovery of the First Potent and Selective Small Molecule Opioid Receptor-like (ORL1) Antagonist: 1-[(3R,4R)-1-Cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl- 1,3-dihydro-2H-benzimidazol-2-one (J-113397)Hiroshi Kawamoto, Satoshi Ozaki, Yoshiki Itoh, Mitsuru Miyaji, Sachie Arai, Hiroshi Nakashima, Tetsuya Kato, Hisashi Ohta, and Yoshikazu IwasawaView Author Information Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories, Banyu Pharmaceutical Company Ltd., Okubo 3, Tsukuba, Ibaraki 300-2611, Japan Cite this: J. Med. Chem. 1999, 42, 25, 5061–5063Publication Date (Web):November 19, 1999Publication History Received14 October 1999Published online19 November 1999Published inissue 1 December 1999https://pubs.acs.org/doi/10.1021/jm990517phttps://doi.org/10.1021/jm990517prapid-communicationACS PublicationsCopyright © 1999 American Chemical SocietyRequest reuse permissionsArticle Views825Altmetric-Citations182LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Antagonists,Peptides and proteins,Receptors,Screening assays,Selectivity Get e-Alerts

Related Papers

• → Designing bifunctional NOP receptor–mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.(2013)37 cited
• → Role of spinal opioid receptor on the antiallodynic effect of intrathecal nociceptin in neuropathic rat(2013)18 cited
• → The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands(2003)10 cited
• → P.1.d.015 Nociceptin and [Nphe1, Arg14, Lys 15]-nociceptin-NH2, UFP-101 restored opioid antinociception in morphine tolerant mice(2006)
• → Analysis of Vasodepressor Responses to Nociceptin and Nociceptin Analogs in the Systemic Vascular Bed of the Anesthetized Rabbit In Vivo(1998)